Huntington's disease: Enzyme offers hope, study finds

Fruit fly eye and body Researchers reduced the death of neurons in fruit flies by blocking a particular enzyme.

Related Stories

A new approach to treating Huntington's disease may have been found, a UK study carried out in fruit flies suggests.

The incurable disease, caused by degeneration of nerve cells, gradually impairs a person's ability to function.

Researchers slowed the development of neurodegeneration - a key factor in Huntington's disease - by targeting a particular enzyme in fruit-flies.

The study, led by the University of Leicester, is published in Current Biology.

"This breakthrough is important as no drugs currently exist that halt progression, or delay onset of Huntington's disease," said Dr Giorgini, who led the study.

The researchers found decreasing the activity of a certain enzyme - known as KMO - reduced the number of neurons dying in the fruit-flies.

"Since we have identified an actual target and there are chemicals that can act on the target, there is a possibility that we could develop drugs to delay the onset of the disease," Dr Giorgini said.

Scientists also found that targeting other related enzymes with chemicals improved Huntington's symptoms in fruit flies.

"We would like to look in closer detail at the other enzymes in the same pathway and to develop new inhibitors of KMO," Dr Giorgini said.

Brain inflamation

Research from America also suggests the enzyme could be a key target for therapies.

The US research, published in Cell, found symptoms of Huntington's disease in mouse models could be reduced by blocking the same enzyme.

They developed a new compound - known as JM6 - that blocks the enzyme, leading to reduced brain inflammation in mice.

Working with mouse models of another neurodegenerative condition - Alzheimer's disease - they found that JM6 also prevents memory loss.

"The discovery has significant implications for two devastating diseases and suggest that the KMO enzyme is a good protein for us to target with medications in diverse neurodegenerative disorders," said Professor Lennart Mucke, of the Gladstone Institute, where the research took place.

Huntington's Disease Association chief executive Cath Stanley said: "This is an exciting piece of research that will offer hope to the many people affected by Huntington's disease."

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Health stories


Features & Analysis

Elsewhere on the BBC

  • Audi R8Need for speed

    Audi unveils its fastest production car ever - ahead of its Geneva debut


  • A bicycle with a Copenhagen WheelClick Watch

    The wheel giving push bikes an extra boost by turning them into smart electric hybrids

Try our new site and tell us what you think. Learn more
Take me there

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.